Bluejay Diagnostics enrolls 545 patients in SYMON™ II study, exceeds expectations

Bluejay Diagnostics, Inc.

Enrolled 545 of 750 target patients in SYMON™ II multicenter IL-6 monitoring study, exceeding initial expectations.
Completed monoclonal and polyclonal antibody production, providing capacity for >10 million test cartridges.
Manufacturing readiness includes cartridge characterization for U.S. commercial production and ongoing fabrication for FDA submission.
Company transitions focus to data analysis, regulatory engagement, and commercialization preparedness in 2026.
Technology transfer activities progress without single point of failure, mitigating scale-up risk.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.